The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
15 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,985,646 in first-year total cost, median $234,000.
Most frequent study sections
- Special Emphasis Panel[ZRG1 EMNR-S (55)]8
- Special Emphasis Panel[ZRG1 EMNR-D (56)]4
- Special Emphasis Panel[ZRG1 MCST-M (81)]2
- Special Emphasis Panel[ZRG1 EMS-S (55)]1
Most frequent institutions
- BAYLOR COLLEGE OF MEDICINE1
- CITY COLLEGE OF NEW YORK1
- NORTHWESTERN UNIVERSITY AT CHICAGO1
- OREGON HEALTH & SCIENCE UNIVERSITY1
- RHODE ISLAND HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Leveraging artificial intelligence methods and electronic health records for pediatric pharmacovigilance1R21HD113234-01 | BEJAN, COSMIN ADRIAN | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $481,250 | ZRG1 |
| 2023 | Investigation of urinary extracellular vesicles as novel and safe therapeutics for autosomal recessive polycystic kidney disease1R21HD113263-01 | CHUNG, EUN JI PAIGE | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $465,690 | ZRG1 |
| 2023 | Functional connection between the growth factor independence-1b and post-neonatal regulation of biotransformation genes1R21HD112071-01 | YAN, BINGFANG | UNIVERSITY OF CINCINNATI, OH | $445,500 | ZRG1 |
| 2023 | Metformin Effects Placental Trophoblast Function1R21HD108853-01A1 | VALENT, AMY MIYOSHI | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $192,500 | ZRG1 |
| 2022 | Dexmedetomidine Use in Infants undergoing Cooling due to Neonatal Encephalopathy (DICE trial)1R21HD107754-01 | BASERGA, MARIANA | UNIVERSITY OF UTAH, UT | $243,917 | ZRG1 |
| 2022 | Delineating host, parasite and pharmacologic factors impacting the treatment of malaria in children with and without HIV1R21HD110110-01 | PARIKH, SUNIL | YALE UNIVERSITY, CT | $243,130 | ZRG1 |
| 2022 | ENDEAVOR TO STOP NAUSEA/VOMITING ASSOCIATED WITH PREGNANCY (E-SNAP)1R21HD105101-01A1 | WISNER, KATHERINE L | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $240,000 | ZRG1 |
| 2022 | Brain exosome biomarker targets to optimize pharmacologic treatment of depression in pregnancy1R21HD106779-01A1 | GOETZL, LAURAMACHADO VIEIRA, RODRIGO | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $234,000 | ZRG1 |
| 2022 | Serological and functional impact of COVID-19 vaccination on the maternal fetal unit and infant immunity1R21HD107761-01A1 | BERGMANNLEITNER, ELKEBOELIG, RUPSA CHAUDHURY | THOMAS JEFFERSON UNIVERSITY, PA | $225,781 | ZRG1 |
| 2022 | Pharmacokinetic/Pharmacodynamic model in pregnant women with depression to guide sertraline dosing1R21HD105297-01A1 | BIRNBAUM, ANGELA KILLAMOLA, SILVIA MARTINEZ | UNIVERSITY OF MINNESOTA, MN | $223,466 | ZRG1 |
| 2022 | Developmental Pharmacology of Hydroxyurea Across the Age Span for the Treatment of Sickle Cell Anemia1R21HD107675-01 | DONG, MINMCGANN, PATRICK THOMAS | RHODE ISLAND HOSPITAL, RI | $195,993 | ZRG1 |
| 2021 | Development of the MasSpec Pen Technology for Rapid and Accurate Identification of Pediatric Infections1R21HD106614-01 | SCHIAVINATO EBERLIN, LIVIA | BAYLOR COLLEGE OF MEDICINE, TX | $258,793 | ZRG1 |
| 2021 | The Therapeutic Potential of Pasteurized Human Donor Breast Milk Exosomes1R21HD104481-01A1 | MARTIN, COLIN ASIMS, BRIAN | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $222,750 | ZRG1 |
| 2021 | Novel bone specific pharmacological treatment for osteogenesis imperfecta1R21HD106607-01 | CARRIERO, ALESSANDRAFORLINO, ANTONELLA | CITY COLLEGE OF NEW YORK, NY | $195,876 | ZRG1 |
| 2021 | Evaluating teratogenic risk of anti-seizure medications in single-rosette brain organoids1R21HD106580-01 | TIDBALL, ANDREW M | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $117,000 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.